Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » By Affiliations
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top 20 Journal Cited
 » Top 20 Cited
 » Top 20 Author Cited
 » Usage Since Sept 2007


 
 
 

Login | Create Account

What We Know About The Molecular Genetics Of Central Nervous System (CNS) Tumours In Malaysia

Sarina, S. and Aziz, M.Y. and Norafiza, Z. and Jafri Malin Abdullah, and Jain George, P. and Hasnan Jaafar, and Mohd. Nizam Isa, (2004) What We Know About The Molecular Genetics Of Central Nervous System (CNS) Tumours In Malaysia. Malaysian Journal of Medical Sciences, 11 (1). pp. 37-43. ISSN 1394195X

Full text not available from this repository.

Official URL: http://www.medic.usm.my/publication/mjms/

Affiliations

Universiti Sains Malaysia, School of Medical Sciences, Human Genome Center

Abstract

The new millennium has been regarded as a genomic era. A lot of researchers and pathologists are beginning to understand the scientific basis of molecular genetics and relates with the progression of the diseases. Central nervous system (CNS)tumours are among the most rapidly fatal of all cancers. It has been proposed that the progression of malignant tumours may result from multi-step of genetic alterations, including activation of oncogenes, inactivation of tumour suppressor genes and also the presence of certain molecular marker such as telomerase activity. In this paper, we review some recent data from the literature, including our own studies, on the molecular genetics analysis in CNS tumours. Our studies have shown that two types of tumour suppressor genes, p53 and PTEN were involved in the development of these tumours but not in p16 gene among the patients from Hospital Universiti Sains Malaysia (HUSM). Telomerase activity also has been detected in various types of CNS tumours. Thus, it is important to assemble all data which
related to this study and may provide as a vital information in a new approach to neuro-oncology studies in Malaysia.

Item Type:Journal
Keywords:Molecular genetics, CNS tumours, Malaysia
Subjects:R Medicine
ID Code:626

1. Taylor, F. Brain and Spinal Cord Tumors: Hope Through Research. Bethesda: National Institute of Neurological Disorder and Stroke (NINDS), 1993.

2. Leon, S.P., Zhu, J., Black, P.M. Genetic aberrations in

human brain tumors. Neurosurgery 1994;34(4): 708-722.

3. Yuasa, Y. Genetic diagnosis and gene therapy for cancer. Asian Med J 2000;43(9): 430-439.

4. Fueyo, J., Gomez-Manzano, C., Yung, W.K.A., Kyritsis, A.P. The functional role of tumor suppressorgenes in gliomas-Clues for future therapeutic strategies. Neurology 1998;51: 1250-1255.

5. Fathallah-Shaykh, H. New molecular strategies to cure

brain tumors. Arch Neurol 1999;56(4): 449-451.

6. Shay, J.W, Gazdar, A.F. Telomerase in the early detection of cancer. J Clin Pathol 1997;50(2): 106-108.

7. Lane, D.P., Crawford, L.V. T antigen is bound to a host

protein in SV40-transformed cell. Nature 1979;278:261-263.

8. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., Vogelstein B. Waf1, a potential mediator

of p53 tumor suppression. Cell 1993;75: 817-825.

9. Karp J.E, Broder S. New directions in molecular medicine. Cancer Res 1994;54: 653-665.

10. Yin Y., Tainsky M.A., Bischoff F.Z., Strong L.C., Wahl

G.M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53

alleles. Cell 1992;70: 937-948.

11. El-Deiry, W.S., Harper J.W., O’Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., Wiman K.G., Mercer W.E., Kastan M.B., Kohn K.W., Elledge S.J., Kinzler K.W., Vogelstein B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54: 1169-1174.

12. Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.

M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Deville, P., Glover, T., Collins, F.S., Weston, A., Modali, R., Harris, C.C., Vogelsteein, B. Mutations In The P53 Gene Occur In Diverse Tumour Types. Nature 1989;342: 705-708.

13. Hollstein M., Sidransky D., Vogelstein B., Harris C.C.

P53 Mutations In Human Cancers. Science 1991;253:49-53.

14. Chozick, B.S., Weicker, M.E., Pezzullo, J.C., Jackson,

C.L., Finkelstein, S.D., Ambler, M.W., Epstein, M.H., Finch, P.W. Pattern Of Mutant P53 Expression In Human Astrocytomas Suggests The Existence Of Alternate Pathways Of Tumorigenesis. Cancer 1994;73: 406-415.

15. Frankel, R.H., Bayona, W., Koslow, M., Newcomb,E.W. p53 mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992;52: 1427-1433.

16. Fults, D., Brockmeyer, D., Tullous, M.W., Pedone,C.A., Cawthon, R.M. p53 mutations and loss of heteroygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992;52:674-679.

17. Louis D.N., Von Deimling A., Chung R.Y., Rubio M.P.,

Whaley J.M., Eibl R.H., Ohgaki H., Wiestler O.D.,Thor A.D. & Seizinger B.R. Comparative Study Of P53 Gene And Protein Alterations In Human Astrocytomas. J Neuropathol Exp Neuro 1993;52: 31-38.

18. Mashiyama S., Murakami Y., Yoshimoto T., Sekiya T., Hayashi K. Detection of p53 mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1991;6: 1313-1318.

19. Newcomb, E.W., Madonia W.J., Pisharody S., Lang F.F., Koslow M., Miller D.C. A Correlative Study Of P53 Protein Alteration And P53 Gene Mutation In Glioblastoma Multiforme. Brain Pathol 1993;3: 229-235.

20. von Deimling, A., Eibl, R.H., Ohgaki, H., Louis, D.N.,

von Ammon, K., Petersen, I., Kleihues, P., Chung, R.Y., Wiestler, O.D., Seizinger, B.R. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992;52: 2987-2990.

21. Ellison, D.W., Gatter, K.C., Steart, P.V., Lane, D.P., Weller, R.O. Expression of the p53 protein in a spectrum of astrocytic tumors. J Pathol 1992;168: 383-386.

22. Haapasalo, H., Isola, J., Sallinen, P., Kalimo, H., Helin, H., Rantala, I. Aberrant P53 Expression In Astrocytic Neoplasms Of The Brain: Association With Proliferation. Am J Pathol 1993;142: 1347-1351.

23. Jaros, E., Perry, R.H., Adam, L., Kelly, P.J., Crawford, P.J., Kalbag, R.M., Mendelow, A.D., Sengupta, R.P., Pearson, A.D. Prognostic implications of p53 protein,

epidermal growth factor receptor, and Ki-67 labeling in brain tumors. Br J Cancer 1992;66: 373-385.

24. Rubio, M.P., von Deimling, A., Yandell, D.W., Wiestler,

O.D., Gusella, J.F., Louis, D.N. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993;53: 3465-3467.

25. Chung, R., Whaley, J., Kley, N., Anderson, K., Louis,

D., Menon, A., Hettlich, C., Freiman, R., Hedley-Whyte, E. T., Martuza, R., Jenkins, R., Yandell, D.,Seizinger, B. R. TP53 gene mutations and 17p deletions in human strocytomas. Genes Chrom Cancer 1991;3:323-331.

26. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations In The P53 Tumor Suppressor Gene: Clues To Cancer Etiology And Molecular Pathogenesis. Cancer Res 1994;54: 4855-4878.

27. Soussi T., Caron de Fromental C., May P. Structural aspect of the p53 protein in relation to gene evolution.

Oncogene 1990;5: 945-952.

28. Levine A.J., Momand J., Finlay C.A. The p53 tumor

suppressor gene. Nature 1991;351: 453-456.

29. Finlay C.A., Hinds P.W., Tan T-H, Eliyahu D., Oren

M., Levine A.J. Activating mutations for transformation by p53 produce a gene product that form an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8: 531-539.

30. Reich N.C., Levine A.J. Growth regulation of a cellular

tumor antigen, p53, in transformed cell. Nature 1984;308: 199-201.

31. Bosari S., Viale G. The clinical significance of p53

aberrations in human tumours. Virchows Arch 1995;427: 229-241.

32. Chang F., Syrjanen S., Syrjanen K. Implication of the

p53 tumor suppressor gene in clinical oncology. J Clin Oncol 1993;13: 1009-1022.

33. Orita M., Suzuky Y., Sekiya T., Hayashi K. Rapid and

sensitive detection of point missense mutation and DNA polymorphisms using the polymerase chain reaction. Genomic 1989;5: 874-879.

34. Wu J.K., Zhen Y., Darras B.T. Frequency of p53 tumor

suppressor gene mutations in human primary brain tumors. Neurosurgery 1993;33: 824-831.

35. Lang F.F., Miller D.C., Pisharody S., Koslow M., Newcomb E.W. High Frequency Of P53 Protein Accumulation Without P53 Gene Mutation In Human Juvenile Pilocytic, Low Grade And Anaplastic Astrocytomas. Oncogene 1994;9: 949-954.

36. Koga H., Zhang S., Kumanishi T., Washiyama K.,Ichikawa T., Tanaka R., Mukawa J. Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 1994;87:225-232.

37. Sakar F.H., Kupsky W.J., Li Y.W., Sreepathi P. Analysis

of p53 gene mutations in human gliomas by polymerase chain reaction-based single-strand conformation polymorphism and DNA sequencing.Diag Mol Path 1994;3: 2-8.

38. Li Y., Millikan R.C., Carozza S., Newman B., Liu E.,

Davis R., Miike R., Wrensch M. P53 Mutation In Maglinant Gliomas. Cancer Epidemiol Biomarkers Prev 1998;7(4): 303-308.

39. Tangnipon W., Mizoguchi M., Kukita Y., Inazuka M.,

Iwaki T., Fukui M., Hayashi K. Distinct pattern of PCR-SSCP analysis of p53 mutation in human astrocytomas. Cancer Lett 1999;141: 195-201.

40. Mohd. Nizam I., Yusoff A.A., Sidek M.R., Jain Malin A. Non-isotopic PCR-cold SSCP of p53 gene mutations in Gliomas using the Dcode System. Asia Pacific J Mol Biol & Biotechnol 2001;9(2): 107-110.

41. Aziz M.Y., Jafri Malin A., Mohd Ros S., Mohd Nizam I. Mutations of the p53 gene in gliomas from Malay patients. The Med J Malaysia 2003;58(2): 225-232.

42. Cheng Y., Ng H., Ding M., Zhang S. Molecular analysis

of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 1999;58:120-28.

43. Fujisawa H., Reis R.M., Nakamura M., Colella S., Yonekawa Y., Kleihues P., Ohgaki H. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000;80: 65-72.

44. Schmidt E.E., Ichimura K., Goike H.M., Moshref A. Mutational profile of the PTEN gene in primary human

astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol 1999;58: 1170-1182.

45. Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R. Somatic mutations of PTEN in

glioblastoma multiforme. Cancer Res 1997;57: 4183-4186.

46. Schmidt E.E., Ichimura K., Reifenberger G., Collins

V.P. CDKN2 (p16/MTSI) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54: 6321-6324.

47. Lee S., Kim J., Rhee C., Kang Y., Lee J., Hong S.,

Choi K. Loss of heterozygosity on chromosome 10,13q (Rb), 17p and p53 gene mutations in human brain gliomas. J Korean Medical Sc 1995;10: 442-448.

48. Walker D.G., Duan W., Popovic E.A., Kaye A.H., Tomlinson F.H., Lavin M. Homozygous deletions of the multiple tumor suppressor gene in the progression of human astrocytomas. Cancer Res 1995;55: 20-23.

49. Watling C.J., van Meyel D.J., Ramsay D.A., Macdonald D.R., Cairncross J.G. Loss of heterozygosity analysis of chromosomes 9, 10 and 17 in gliomas in families. Can J Neurol Sc 1995;22: 17-21.

50. Ali I.U., Schriml L.M., Dean M: Mutational spectra

of PTEN/MMAC1 gene. A tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999;91: 1922-32.

51. Ishii N., Maier D., Merio A., Tada M., Sawamura Y.,

Diserens A., Van Meir E.G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-479.

52. Ichimura K., Schmidt E.E., Miyakawa A., Goike H.M.,

Collins V.P. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chrom Cancer 1995;22: 9-15.

53. Maher E.A., Furnari F.B., Bachoo R.M., Rowitch D.H.,

Louis D.N., Cavenee W.K. DePinho R.A. Malignant glioma: genetics and biology of a grave matter. Genes Devel 2001;15: 1311-1333.

54. Bostrom J., Cobbers J.M., Wolter M., Tabatabai G.,

Weber R.G., Lichter P., Collins V.P. & Reifenberger G. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 1998;58: 29-33.

55. Kato H., Kato S., Kumabe T., Sonoda Y., Yoshimoto T., Han S., Suzuki T., Shibata H., Kanamaru R. & Ishioka C. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 2000;6:3937-3943.

56. Liggett, W.H., Sidransky, D. Role of the p16 tumor

suppressor gene in cancer. J Clin Oncol 1998;16(3):

1197-1206.

57. Guang, Z., Xianhou, Y. Study of deletion of P16 gene

in the progression of brain astrocytomas. Chinese J Cancer Res 1998;10: 412-417.

58. Ng, H-K. & Lam, P.Y.P. The molecular genetics of central nervous system tumors. Pathology 1998;30:196-202.

59. Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A., Ally D.S., Sheahan M.D., Clark W.H. Jr, Tucker M.A., Dracopoli N.C. Germline p16 mutations in familial melanomas. Nature Genet 1994;8: 15-21.

60. Caldas, C., Hahn, S.A., Dacosta, L.T., Redston, M.S.,

Schutte, M., Seymour A.B., Weinstein, C.L., Hruban,

R.H., Yeo, C.J. & Kern, S.E. Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994;8: 27-32.

61. Mori T., Miura K., Aoki T., Nishihira T., Mori S.,

Nakamura Y. Frequent somatic mutation of the MTS1/CDK4 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamoous cellcarcinomas. Cancer Res 1994;54: 3396-3397.

62. Hayashi N., Sigimota Y., Tsuchiya E., Ogawa M, Nakamura Y. Somatic mutations of the MTS1 (multiple tumor suppressor 1)/CDK4I (cyclin dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Comm 1994;202:1426-1430.

63. Izumoto S., Arita N., Ohnishi T., Hiraga S., Taki T. &

Hayakwa T. Homozygous deletion of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues. Cancer Lett 1995;97: 241-247.

64. Jafri Malin A., Norafiza Z., Sarina S., Hasnan J. &

Mohd Nizam I. Molecular genetic analysis of phosphatase and tensin homolog and p16 tumour suppressor genes in patients with malignant glioma. Neurosurgical Focus 2003;14(4): Article 6.

65. Jen, J., Harper, J.W., Bigner, S.H., Bigner, D.D.,

Papadopoulos, N., Markowitz, S., Willson, J.K.W., Kinzler, K.W. & Vogelstein, B. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994;54: 6353-6358.

66. Spruck, C.H. III., Gonzalez-Zulueta, M., Shibata, A.,

Simoneau, A.R., Lin, M-F., Gonzales, F., Tsai, Y.C. & Jones, P.A. p16 gene in uncultured tumours. Nature

1994;370: 183-184.

67. Schmidt, E.E., Ichimura, K., Messerle, K.R., Goike,

H.M. & Collins, V.P. Infrequent methylation of CDKN2A (MTS1/p16) and rare mutation of both CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours. Br J Cancer 1997;75(1): 2-8.

68. Urquidi V, Tarin D, Goodison S. Role of telomerase in cell senescence and oncogenesis. Annu Rev Med 2000;51: 65-70.

69. Falchetti, M.L., Pallini, R., Larocca, L.M., Verna, R.

& D’Ambrosio, E. Telomerase expression in intracranial tumours: Prognostic potential for malignant gliomas and meningiomas. J Clin Pathol 1999;53(2): 234-236.

70. Sano, T., Asai, A., Mishima, K., Fujimaki, T. & Kirino,

T. Telomerase activity in 144 brain tumours. Br J Cancer 1998;77(10): 1633-1637.

71. Chen, H-J., Cho, C-L., Liang, C-L., Chen, L., Chang,

H-W., Lu, K. & Lee, T-C. Differential telomerase expression and telomere length in primary intracranial tumors. The Chang Gung Med J 2001;24(6): 352-359.

72. Hiraga, S., Ohnishi, T., Izumoto, S., Miyahara, E.,

Kanemura, Y., Matsumura, H. & Arita, N. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res 1998;58: 2117-2125.

73. Langford, L.A., Piatyszek, M.A., Xu, R., Schold, S.C.,

Wright, W.E., & Shay, J.W. Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol 1997;28(4): 416-420.

74. Kim, N.W. Clinical implication of telomerase in cancer.

Eur J Cancer 1997;33(5): 781-786.

75. Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D., Ho, L.C., Coviello, G.M., Wright, W.E., Weinrich, S.L. & Shay, J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266: 2011-2015.

76. Wen, J.M., Sun, L.B., Zhang, M. & Zheng, M.H. A non-isotopic method for the detection activity in tumour tissues: TRAP-silver staining assay. J Clin Pathol 1998;51(2): 110-113.

77. Dalla Torre, C.A., Maciel, R.M.B., Pinheiro, N.A.,

Andrade, J.A.D., de Toledo, S.R.C., Villa, L.L. & Cerutti, J.M. TRAP-silver staining, a highly sensitive assay for measuring telomerase activity in tumor tissue and cell lines. Brazillian J Med Biol Res 2002;35: 65-68.

78. Fujita, M., Tomita, S., Ueda, Y., Fujimori, T. & Zheng,

M-H. Gel staining methods for detection of telomerase activity with the telomeric repeat amplification protocol (TRAP) assay/Reply. J Clin Pathol 1998;51:342-343.

79. Sarina S., Jafri Malin A., Mohamad Ros S., Jain George

P. & Mohd Nizam I. A non-isotopic method for the detection of telomerase activity in human brain tumours: TRAP-Silver staining assay. Malaysian J Biochem and Mol Biol 2003;8: 45-48.

Repository Staff Only: item control page
 
 
 
 
 
   
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.